Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force.
Kamilla Woznica MiskowiakZacharias K ObelRiccardo GuglielmoCaterina Del Mar BonninChristopher R BowieVicent Balanzá-MartínezKatherine E BurdickAndre Fèrrer CarvalhoAnnemieke DolsKatie M DouglasPeter GallagherLars Vedel KessingBeny LaferKathryn E LewandowskiCarlos López-JaramilloAnabel Martinez-AranRoger S McIntyreRichard A BryantScot E PurdonAyal SchafferPaul R A StokesTomiki SumiyoshiIvan J TorresTamsyn E Van RheenenLakshmi N YathamAllan H YoungEduard VietaGregor HaslerPublished in: Bipolar disorders (2024)
Methylphenidate or mixed amphetamine salts may improve ADHD symptoms in BD. However, there is limited evidence regarding the effectiveness on cognition. The medications produced no increased mania risk when used alongside mood stabilizers. Further robust studies are needed to assess cognition in BD patients receiving psychostimulant treatment alongside mood stabilizers.
Keyphrases
- attention deficit hyperactivity disorder
- bipolar disorder
- major depressive disorder
- autism spectrum disorder
- mild cognitive impairment
- cognitive impairment
- white matter
- working memory
- sleep quality
- randomized controlled trial
- systematic review
- cancer therapy
- ionic liquid
- physical activity
- combination therapy
- electronic health record